People line GHK-Cu and BPC-157 up because both get described as “healing peptides” in the same online protocols. But they barely occupy the same category once you look at how they are actually used and regulated: one is a copper peptide you can buy in a skincare serum today, the other is a research peptide with a date in front of an FDA committee. The table above is the row-by-row breakdown. Below is what each row means.
GHK-Cu vs BPC-157: the short version
GHK-Cu (copper tripeptide-1) is, in practice, a cosmetic ingredient — legal to sell over the counter in topical form, with systemic data that is preclinical and human evidence that comes from open-label studies of multi-ingredient creams and gels. BPC-157 is an unapproved research peptide with a larger animal corpus and a thin human layer. Neither has a published randomized controlled trial of the molecule itself, and neither is an approved drug.
Evidence: preclinical systemic data vs a thin human layer
Most of what is known about either molecule comes from non-human studies. BPC-157 has the larger preclinical base — a broad rodent corpus on tendon, gut and wound healing — plus a small amount of human data: a couple of uncontrolled pilots and one recruiting Phase 2 trial for acute hamstring strain. GHK-Cu’s systemic evidence is preclinical, and its human-level records are mostly open-label trials of cosmetic formulations where the copper peptide is one of several actives — useful for the product, weak as evidence for the molecule. For how we weigh these tiers, see our how we grade evidence explainer, the full GHK-Cu evidence and regulatory record, and the BPC-157 evidence and regulatory record.
What each is studied for
The two are investigated for overlapping but distinct reasons. GHK-Cu is a copper-carrying tripeptide studied mainly in skin: wound healing, tissue remodeling, antioxidant effects, and anti-aging cosmetic applications. BPC-157 is studied as a cytoprotective, angiogenic agent in animal models of tendon, ligament and gut repair. So they get stacked for “healing,” but one is a topical skin actor and the other a systemic tissue-repair candidate — different routes, different targets.
Regulation: only one is on the July 2026 vote
This is where the gap is clearest. BPC-157 was removed from the FDA 503A “do not compound” list in April 2026, but that did not make it compoundable; the Pharmacy Compounding Advisory Committee votes on it on July 23, 2026, for the evaluated indication of ulcerative colitis. We track that meeting in the July 2026 FDA peptide meeting, explained. Injectable GHK-Cu is a different story: per Frier Levitt’s 2026 analysis, it is not on the July agenda and is slated for a separate PCAC consultation before the end of February 2027. Meanwhile topical GHK-Cu remains widely sold over the counter as the cosmetic ingredient copper tripeptide-1. On anti-doping, BPC-157 is explicitly prohibited under the WADA S0 category at all times; GHK-Cu is not individually listed, though a non-approved injectable would fall under the same S0 catch-all. Neither carries an EU marketing authorization as a drug.
So which one, if either?
They answer different questions. If the interest is a topical skincare ingredient with a long cosmetic track record, GHK-Cu is the one that actually exists on the shelf today — as a cosmetic, not a proven systemic therapeutic. If the interest is systemic tissue repair, BPC-157 has more preclinical depth but remains unapproved, thinly evidenced in humans, and banned in sport. Neither is an established human drug in 2026. Watch the July 2026 vote for BPC-157, and the later PCAC review for injectable GHK-Cu, for the next real regulatory change.
Research information only. Neither GHK-Cu nor BPC-157 is approved as a drug for human use. Talk to a licensed physician before considering any peptide.